$ケモマブ・セラピューティクス(CMMB.US)$Chemomab Reports New Peer-Reviewed Publication Reinforcing The Clinical Association Of Its CCL24 Target With Disease Severity and Mortality In Systemic Sclerosis
Breakthrough in Liver Disease Treatment: Chemomab's CM-101 Secures New European Patent. In the realm of medical science, groundbreaking advancements often mark pivotal moments in the fight against debilitating diseases. One such recent development in the battle against Primary Sclerosing Cholangitis (PSC), a rare and potentially fatal liver disease, has emerged from the labs of Chemomab Therapeutics. The company has been...
$ケモマブ・セラピューティクス(CMMB.US)$Waiting for the rest of the numbers! (((((. Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.26) per share. This is a 63.89 percent increase over losses of $(0.72) per share from the same period last year. )))))
Trytosaveabitスレ主Keep profits:
It’s pretty good news yes! But patent news can cause a nice price increase but not hold sometimes! Other times it don’t move at all and others it explodes? GL
Trytosaveabitスレ主Keep profits:
First PM and AM are hard to trade! You don’t get a clear picture of liquidity and interest! Not all brokers are open! And yes since the beginning of Covid the market has changed a lot IMO! GL
$ケモマブ・セラピューティクス(CMMB.US)$Chemomab Announces Completion Of Patient Enrollment In CM-101 Phase 2 Primary Sclerosing Cholangitis Trial And Moves Up Expected Topline Readout To Midyear 2024
$ケモマブ・セラピューティクス(CMMB.US)$Well i was hoping when i seen FINTEL was starting to get some shares returned a hour ago. Thought ok now price may go back up? I was wrong, the shares that were returned are already gone again and we are back to zero shares LTB! Grrrrr! Shorts still in control of PA. At least for a bit? Hopefully buy side pressure can increase? GL all
ケモマブ・セラピューティクスに関するコメント
In the realm of medical science, groundbreaking advancements often mark pivotal moments in the fight against debilitating diseases. One such recent development in the battle against Primary Sclerosing Cholangitis (PSC), a rare and potentially fatal liver disease, has emerged from the labs of Chemomab Therapeutics. The company has been...
まだコメントはありません